搜索
Spero Therapeutics Inc
SPRO添加自选
2.200USD
-0.020-0.90%
收盘 07/02, 13:00（美东）报价延迟15分钟
127.38M总市值
7.92市盈率 TTM
关于 Spero Therapeutics Inc 公司
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc简介
公司代码SPRO
公司名称Spero Therapeutics Inc
上市日期Nov 02, 2017
CEORajavelu (Esther)
员工数量32
证券类型Ordinary Share
年结日Nov 02
公司地址675 Massachusetts Ave Ste 14
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02139-3309
电话18572421600
网址https://sperotherapeutics.com/
公司代码SPRO
上市日期Nov 02, 2017
CEORajavelu (Esther)
Spero Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
-36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
常见问题
Spero Therapeutics Inc的前五大股东是谁？
Spero Therapeutics Inc 的前五大股东如下：Dr. Ankit Mahadevia, M.D.
有多少机构持有Spero Therapeutics Inc(SPRO)的股份？
截至2026Q1，共有117家机构持有Spero Therapeutics Inc的股份，合计持有的股份价值约为11.81M，占公司总股份的20.40%。与2025Q4相比，机构持股有所增加，增幅为-1291189.00。
哪个业务部门对Spero Therapeutics Inc的收入贡献最大？
在2026Q1，Collaboration Revenue Related Party业务部门对Spero Therapeutics Inc的收入贡献最大，创收47.03M，占总收入的70.41%。